Deborah French
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Deborah French has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Alan H.B. Wu
3 shared publicationsJustin Dowis
University of California San Francisco
3 shared publicationsAndrew Smith
Clinical Laboratories, UCSF at Zuckerberg San Francisco General Hospital and Trauma Center San Francisco California
2 shared publicationsRoy R. Gerona
Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, UCSF Mt Zion Cancer Research Building, Room S-232, 2340 Sutter Street, San Francisco, CA 94102, USA
2 shared publicationsA Muleti
11AFaR S Pietro Hospital Research Centre, Rome, Italy
1 shared publicationA.M. Agliano'
Dipartimento di Medicina Sperimentale, Università “La Sapienza”, Rome Italy
1 shared publication
Latest Publications
- Open Access
- 31 March 2026
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (5)
Determining EDC exposure: direct analytical methods are essential for accurate analysis of human biospecimens
Purpose: Estimates of human exposure are a major component of chemical risk assessment. Studies of bisphenol A (BPA) have raised concern that exposure has been underestimated because the lack of standards for the measurement of the major BPA metabolites has necessitated the use of flawed analytical tools to indirectly estimate them. Because other endocrine-disrupting chemicals (EDCs) are measured using similar indirect methods, we evaluated the accuracy of indirect analysis for representatives from three different classes of non-persistent EDCs that undergo rapid phase II metabolism: bisphenols, parabens, and phthalates. Methods: A direct LC–MS/MS method that simultaneously measures bisphenol S (BPS), propyl paraben (PrP), and monobutyl phthalate (MBP), and their major metabolites in urine, was used to quantify these EDCs in sixty second-trimester human urine samples. The same samples were also analyzed with a widely used indirect method that requires enzymatic hydrolysis before estimating metabolite levels. Results: Marked discrepancies were evident when maternal urine samples were analyzed by both direct and indirect methods. Indirect analysis underestimated levels of all three EDCs and BPA, with the magnitude of underestimation varying by analyte. Conclusion: The accuracy of widely used “indirect” analytical methods that estimate metabolite levels in human urine is neither predictable nor consistent. Greater precision and accuracy is attained using authentic standards for metabolites. Given the importance of biomonitoring data in estimating human EDC exposure, analytical accuracy is critical. Availability of standards for both the parent compound and its major metabolites should be required before a chemical enters the marketplace.
- 31 March 2026
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (5)
Open AccessDetermining EDC exposure: direct analytical methods are essential for accurate analysis of human biospecimens
Purpose: Estimates of human exposure are a major component of chemical risk assessment. Studies of bisphenol A (BPA) have raised concern that exposure has been underestimated because the lack of standards for the measurement of the major BPA metabolites has necessitated the use of flawed analytical tools to indirectly estimate them. Because other endocrine-disrupting chemicals (EDCs) are measured using similar indirect methods, we evaluated the accuracy of indirect analysis for representatives from three different classes of non-persistent EDCs that undergo rapid phase II metabolism: bisphenols, parabens, and phthalates. Methods: A direct LC–MS/MS method that simultaneously measures bisphenol S (BPS), propyl paraben (PrP), and monobutyl phthalate (MBP), and their major metabolites in urine, was used to quantify these EDCs in sixty second-trimester human urine samples. The same samples were also analyzed with a widely used indirect method that requires enzymatic hydrolysis before estimating metabolite levels. Results: Marked discrepancies were evident when maternal urine samples were analyzed by both direct and indirect methods. Indirect analysis underestimated levels of all three EDCs and BPA, with the magnitude of underestimation varying by analyte. Conclusion: The accuracy of widely used “indirect” analytical methods that estimate metabolite levels in human urine is neither predictable nor consistent. Greater precision and accuracy is attained using authentic standards for metabolites. Given the importance of biomonitoring data in estimating human EDC exposure, analytical accuracy is critical. Availability of standards for both the parent compound and its major metabolites should be required before a chemical enters the marketplace.
- 15 March 2025
- Published by Elsevier in Clinics In Laboratory Medicine
- Vol. 45 (2) , 359-372
Alcohol and Drug Testing in Motor Vehicle Crashes
- 15 March 2025
- Published by Elsevier in Clinics In Laboratory Medicine
- Vol. 45 (2) , 359-372
Alcohol and Drug Testing in Motor Vehicle Crashes
- 1 December 2023
- Published by Springer Nature
- Vol. 2737, 265-273
A Liquid Chromatography-Tandem Mass Spectrometry Assay for Quantification of Ethyl Glucuronide and Ethyl Sulfate in Urine
Ethyl glucuronide and ethyl sulfate emerged as the biomarkers of choice for detection of ethanol use as the required sample is urine, enabling easy and noninvasive collection. Further, these biomarkers have a longer detection window in urine than blood ethanol. A liquid chromatography-tandem mass spectrometry method was developed and clinically validated using electrospray ionization in negative mode and selected reaction monitoring. A simple dilution was used for sample preparation on 100 microliters of urine. Gradient elution had a run time of 7 min. The reportable range was established to be 180–100,000 ng/mL for ethyl glucuronide and 50–46,600 ng/mL for ethyl sulfate and between-run imprecision was <7% for both analytes. Key words Ethanol Ethyl glucuronide Ethyl sulfate Alcohol LC-MS/MS Mass spectrometry
- 1 December 2023
- Published by Springer Nature
- Vol. 2737, 265-273
A Liquid Chromatography-Tandem Mass Spectrometry Assay for Quantification of Ethyl Glucuronide and Ethyl Sulfate in Urine
Ethyl glucuronide and ethyl sulfate emerged as the biomarkers of choice for detection of ethanol use as the required sample is urine, enabling easy and noninvasive collection. Further, these biomarkers have a longer detection window in urine than blood ethanol. A liquid chromatography-tandem mass spectrometry method was developed and clinically validated using electrospray ionization in negative mode and selected reaction monitoring. A simple dilution was used for sample preparation on 100 microliters of urine. Gradient elution had a run time of 7 min. The reportable range was established to be 180–100,000 ng/mL for ethyl glucuronide and 50–46,600 ng/mL for ethyl sulfate and between-run imprecision was <7% for both analytes. Key words Ethanol Ethyl glucuronide Ethyl sulfate Alcohol LC-MS/MS Mass spectrometry
- Open Access
- 1 April 2023
- Published by Stanford University Press in Journal of Mass Spectrometry and Advances in the Clinical Lab
- Vol. 28, 13-19
Clinical utility of laboratory developed mass spectrometry assays for steroid hormone testing
- 1 April 2023
- Published by Stanford University Press in Journal of Mass Spectrometry and Advances in the Clinical Lab
- Vol. 28, 13-19
Open AccessClinical utility of laboratory developed mass spectrometry assays for steroid hormone testing
- 22 September 2022
- Published by Elsevier
- Vol. 111, 217-263
Drug testing in the era of new psychoactive substances
- 22 September 2022
- Published by Elsevier
- Vol. 111, 217-263
Drug testing in the era of new psychoactive substances
- 3 June 2022
- Published by Oxford University Press (OUP) in Laboratory Medicine
- Vol. 53 (5) , 514-522
Reduced Immune Response and Neutralizing Antibody Activity to the SARS-CoV-2 Vaccination in Patients with a History of Solid Organ Transplant
Objective: Three SARS-CoV-2 vaccinations and boosters are available. We determined whether solid organ transplant patients mounted an immune response to the vaccinations and whether the antibodies had neutralizing activity compared to healthcare worker controls and monoclonal gammopathy patients. Methods: Remnant plasma was obtained from vaccinated solid organ transplant, allogeneic stem cell transplant, monoclonal gammopathy patients, and healthcare worker controls. Samples positive on a SARS-CoV-2 IgG assay (detects spike protein and nucleocapsid) were run on a SARS-CoV-2 in vitro neutralizing antibody assay and a nucleocapsid-specific SARS-CoV-2 IgG assay. Results: Only 25% of solid organ transplant patients produced antibodies to SARS-CoV-2 vaccination. Of these, 90% had neutralizing activity against wild type virus, but reduced activity to the variants compared to monoclonal gammopathy patients and healthcare worker controls, particularly the delta variant, for which only 50% had neutralizing antibody activity. Conclusion: Solid organ transplant patients should consider protecting themselves against future SARS-CoV-2 infection.
- 3 June 2022
- Published by Oxford University Press (OUP) in Laboratory Medicine
- Vol. 53 (5) , 514-522
Reduced Immune Response and Neutralizing Antibody Activity to the SARS-CoV-2 Vaccination in Patients with a History of Solid Organ Transplant
Objective: Three SARS-CoV-2 vaccinations and boosters are available. We determined whether solid organ transplant patients mounted an immune response to the vaccinations and whether the antibodies had neutralizing activity compared to healthcare worker controls and monoclonal gammopathy patients. Methods: Remnant plasma was obtained from vaccinated solid organ transplant, allogeneic stem cell transplant, monoclonal gammopathy patients, and healthcare worker controls. Samples positive on a SARS-CoV-2 IgG assay (detects spike protein and nucleocapsid) were run on a SARS-CoV-2 in vitro neutralizing antibody assay and a nucleocapsid-specific SARS-CoV-2 IgG assay. Results: Only 25% of solid organ transplant patients produced antibodies to SARS-CoV-2 vaccination. Of these, 90% had neutralizing activity against wild type virus, but reduced activity to the variants compared to monoclonal gammopathy patients and healthcare worker controls, particularly the delta variant, for which only 50% had neutralizing antibody activity. Conclusion: Solid organ transplant patients should consider protecting themselves against future SARS-CoV-2 infection.
- 1 November 2020
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 5 (6) , 1145-1148
Adding Value to Clinical Toxicology Testing
- 1 November 2020
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 5 (6) , 1145-1148
Adding Value to Clinical Toxicology Testing
- 1 December 2018
- Published by Stanford University Press in Clinical Mass Spectrometry
- Vol. 11, 12-20
Comparison of four clinically validated testosterone LC-MS/MS assays: Harmonization is an attainable goal
Immunoassays and liquid chromatography-tandem mass spectrometry assays are commonly employed in clinical laboratories for measurement of total testosterone in serum. Results obtained from either of these methodologies compare poorly due to differences in calibration and/or inadvertent detection of interfering substances by the immunoassays. Standardization efforts are underway, but recent studies indicate that accuracy remains an issue. This study compares the results from four independently developed and validated LC-MS/MS assays for total testosterone. The calibration for each assay was verified using National Institute of Standards and Technology Standard Reference Material 971. Initially, one of the four assays had a mean percent difference of +11.44%, compared to the All Method Mean, but following re-verification of all five non-zero calibrator concentrations with the NIST SRM 971, the mean percent difference decreased to −4.88%. Subsequently, the agreement between all four assays showed a mean bias of <5% across the range of all testosterone concentrations (0.13–38.10 nmol/L; 3.7–1098 ng/dL), including at low concentrations of <1 nmol/L (<29 ng/dL). Excellent agreement between four independently developed LC-MS/MS assays demonstrates that harmonization using standard reference material is attainable. However, as we found in this study, to ensure accurate calibration it is critical to validate the concentrations of new lots of calibrators.
- 1 December 2018
- Published by Stanford University Press in Clinical Mass Spectrometry
- Vol. 11, 12-20
Comparison of four clinically validated testosterone LC-MS/MS assays: Harmonization is an attainable goal
Immunoassays and liquid chromatography-tandem mass spectrometry assays are commonly employed in clinical laboratories for measurement of total testosterone in serum. Results obtained from either of these methodologies compare poorly due to differences in calibration and/or inadvertent detection of interfering substances by the immunoassays. Standardization efforts are underway, but recent studies indicate that accuracy remains an issue. This study compares the results from four independently developed and validated LC-MS/MS assays for total testosterone. The calibration for each assay was verified using National Institute of Standards and Technology Standard Reference Material 971. Initially, one of the four assays had a mean percent difference of +11.44%, compared to the All Method Mean, but following re-verification of all five non-zero calibrator concentrations with the NIST SRM 971, the mean percent difference decreased to −4.88%. Subsequently, the agreement between all four assays showed a mean bias of <5% across the range of all testosterone concentrations (0.13–38.10 nmol/L; 3.7–1098 ng/dL), including at low concentrations of <1 nmol/L (<29 ng/dL). Excellent agreement between four independently developed LC-MS/MS assays demonstrates that harmonization using standard reference material is attainable. However, as we found in this study, to ensure accurate calibration it is critical to validate the concentrations of new lots of calibrators.
- 1 November 2018
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 3 (3) , 460-473
The (Sun)Light and Dark of 25-Hydroxyvitamin D Testing
Background: Vitamin D is obtained by the body via sunlight on the skin, from the diet, or from supplementation. The primary function of vitamin D is to maintain calcium homeostasis and bone health, but in the past decade, numerous other health benefits have been proposed. Content: With the increased awareness of the potential benefits of maintaining sufficient concentrations of 25-hydroxyvitamin D, clinicians began ordering this test for their patients much more frequently. The number of available methods increased, but with that came a larger focus on the challenges of measuring 25-hydroxyvitamin D accurately due to binding to vitamin D-binding protein and the presence of other vitamin D metabolites. Further, standardization of these assays became a focus for several organizations so that clinical guidelines can be applicable to every patient regardless of what methodology is used in 25-hydroxyvitamin D measurement. Summary: Improvements are being made in the specificity, accuracy, and standardization of the measurement of 25-hydroxyvitamin D, and the future of this testing is looking brighter.
- 1 November 2018
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 3 (3) , 460-473
The (Sun)Light and Dark of 25-Hydroxyvitamin D Testing
Background: Vitamin D is obtained by the body via sunlight on the skin, from the diet, or from supplementation. The primary function of vitamin D is to maintain calcium homeostasis and bone health, but in the past decade, numerous other health benefits have been proposed. Content: With the increased awareness of the potential benefits of maintaining sufficient concentrations of 25-hydroxyvitamin D, clinicians began ordering this test for their patients much more frequently. The number of available methods increased, but with that came a larger focus on the challenges of measuring 25-hydroxyvitamin D accurately due to binding to vitamin D-binding protein and the presence of other vitamin D metabolites. Further, standardization of these assays became a focus for several organizations so that clinical guidelines can be applicable to every patient regardless of what methodology is used in 25-hydroxyvitamin D measurement. Summary: Improvements are being made in the specificity, accuracy, and standardization of the measurement of 25-hydroxyvitamin D, and the future of this testing is looking brighter.